世界のペプチドベース代謝障害治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Peptide Based Metabolic Disorders Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4501 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、ペプチドベース代謝障害治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（エキセナチド、リラグルチド、その他）、用途別市場規模（病院薬局、ドラッグストア、オンライン薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・ペプチドベース代謝障害治療薬の市場動向 ・企業の競争状況、市場シェア ・ペプチドベース代謝障害治療薬の種類別市場規模（エキセナチド、リラグルチド、その他） ・ペプチドベース代謝障害治療薬の用途別市場規模（病院薬局、ドラッグストア、オンライン薬局） ・ペプチドベース代謝障害治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・ペプチドベース代謝障害治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・ペプチドベース代謝障害治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ペプチドベース代謝障害治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・ペプチドベース代謝障害治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca、Ingro Finanz (Bachem)、Eli Lilly、Ipsen、Merck、Novo Nordisk、PolyPeptide Group、Teva Pharmaceutical） ・結論

A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability.
North America is expected to dominate the global market in terms of higher market share.

Market Analysis and Insights: Global Peptide Based Metabolic Disorders Therapeutics Market
The global Peptide Based Metabolic Disorders Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Peptide Based Metabolic Disorders Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Peptide Based Metabolic Disorders Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Peptide Based Metabolic Disorders Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Peptide Based Metabolic Disorders Therapeutics market.

Global Peptide Based Metabolic Disorders Therapeutics Scope and Market Size
Peptide Based Metabolic Disorders Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Peptide Based Metabolic Disorders Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Exenatide
Liraglutide
Others

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
Ingro Finanz (Bachem)
Eli Lilly
Ipsen
Merck
Novo Nordisk
PolyPeptide Group
Teva Pharmaceutical

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Exenatide
1.2.3 Liraglutide
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Perspective (2016-2027)
2.2 Peptide Based Metabolic Disorders Therapeutics Growth Trends by Regions
2.2.1 Peptide Based Metabolic Disorders Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Peptide Based Metabolic Disorders Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Peptide Based Metabolic Disorders Therapeutics Industry Dynamic
2.3.1 Peptide Based Metabolic Disorders Therapeutics Market Trends
2.3.2 Peptide Based Metabolic Disorders Therapeutics Market Drivers
2.3.3 Peptide Based Metabolic Disorders Therapeutics Market Challenges
2.3.4 Peptide Based Metabolic Disorders Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Peptide Based Metabolic Disorders Therapeutics Players by Revenue
3.1.1 Global Top Peptide Based Metabolic Disorders Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Peptide Based Metabolic Disorders Therapeutics Revenue
3.4 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio
3.4.1 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Based Metabolic Disorders Therapeutics Revenue in 2020
3.5 Peptide Based Metabolic Disorders Therapeutics Key Players Head office and Area Served
3.6 Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service
3.7 Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Peptide Based Metabolic Disorders Therapeutics Breakdown Data by Type
4.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Type (2022-2027)

5 Peptide Based Metabolic Disorders Therapeutics Breakdown Data by Application
5.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size (2016-2027)
6.2 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Type
6.2.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
6.3 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Application
6.3.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
6.4 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country
6.4.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size (2016-2027)
7.2 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type
7.2.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
7.3 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application
7.3.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
7.4 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country
7.4.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Type
8.2.1 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Application
8.3.1 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region
8.4.1 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size (2016-2027)
9.2 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Type
9.2.1 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Application
9.3.1 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country
9.4.1 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Type
10.2.1 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Application
10.3.1 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country
10.4.1 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Ingro Finanz (Bachem)
11.2.1 Ingro Finanz (Bachem) Company Details
11.2.2 Ingro Finanz (Bachem) Business Overview
11.2.3 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Introduction
11.2.4 Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
11.2.5 Ingro Finanz (Bachem) Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Introduction
11.3.4 Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
11.3.5 Eli Lilly Recent Development
11.4 Ipsen
11.4.1 Ipsen Company Details
11.4.2 Ipsen Business Overview
11.4.3 Ipsen Peptide Based Metabolic Disorders Therapeutics Introduction
11.4.4 Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
11.4.5 Ipsen Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Peptide Based Metabolic Disorders Therapeutics Introduction
11.5.4 Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
11.5.5 Merck Recent Development
11.6 Novo Nordisk
11.6.1 Novo Nordisk Company Details
11.6.2 Novo Nordisk Business Overview
11.6.3 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Introduction
11.6.4 Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
11.6.5 Novo Nordisk Recent Development
11.7 PolyPeptide Group
11.7.1 PolyPeptide Group Company Details
11.7.2 PolyPeptide Group Business Overview
11.7.3 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Introduction
11.7.4 PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
11.7.5 PolyPeptide Group Recent Development
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Details
11.8.2 Teva Pharmaceutical Business Overview
11.8.3 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Introduction
11.8.4 Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
11.8.5 Teva Pharmaceutical Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Exenatide
Table 3. Key Players of Liraglutide
Table 4. Key Players of Others
Table 5. Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Regions (2022-2027)
Table 11. Peptide Based Metabolic Disorders Therapeutics Market Trends
Table 12. Peptide Based Metabolic Disorders Therapeutics Market Drivers
Table 13. Peptide Based Metabolic Disorders Therapeutics Market Challenges
Table 14. Peptide Based Metabolic Disorders Therapeutics Market Restraints
Table 15. Global Peptide Based Metabolic Disorders Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Peptide Based Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2020)
Table 18. Ranking of Global Top Peptide Based Metabolic Disorders Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Peptide Based Metabolic Disorders Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service
Table 22. Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Peptide Based Metabolic Disorders Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. AstraZeneca Company Details
Table 63. AstraZeneca Business Overview
Table 64. AstraZeneca Peptide Based Metabolic Disorders Therapeutics Product
Table 65. AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 66. AstraZeneca Recent Development
Table 67. Ingro Finanz (Bachem) Company Details
Table 68. Ingro Finanz (Bachem) Business Overview
Table 69. Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Product
Table 70. Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Ingro Finanz (Bachem) Recent Development
Table 72. Eli Lilly Company Details
Table 73. Eli Lilly Business Overview
Table 74. Eli Lilly Peptide Based Metabolic Disorders Therapeutics Product
Table 75. Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Eli Lilly Recent Development
Table 77. Ipsen Company Details
Table 78. Ipsen Business Overview
Table 79. Ipsen Peptide Based Metabolic Disorders Therapeutics Product
Table 80. Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Ipsen Recent Development
Table 82. Merck Company Details
Table 83. Merck Business Overview
Table 84. Merck Peptide Based Metabolic Disorders Therapeutics Product
Table 85. Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Merck Recent Development
Table 87. Novo Nordisk Company Details
Table 88. Novo Nordisk Business Overview
Table 89. Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Product
Table 90. Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Novo Nordisk Recent Development
Table 92. PolyPeptide Group Company Details
Table 93. PolyPeptide Group Business Overview
Table 94. PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Product
Table 95. PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 96. PolyPeptide Group Recent Development
Table 97. Teva Pharmaceutical Company Details
Table 98. Teva Pharmaceutical Business Overview
Table 99. Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Teva Pharmaceutical Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Exenatide Features
Figure 3. Liraglutide Features
Figure 4. Others Features
Figure 5. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Peptide Based Metabolic Disorders Therapeutics Report Years Considered
Figure 10. Global Peptide Based Metabolic Disorders Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Peptide Based Metabolic Disorders Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Players in 2020
Figure 15. Global Top Peptide Based Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Peptide Based Metabolic Disorders Therapeutics Revenue in 2020
Figure 17. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Share by Region (2016-2027)
Figure 39. China Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. AstraZeneca Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
Figure 59. Ingro Finanz (Bachem) Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
Figure 60. Eli Lilly Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
Figure 61. Ipsen Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
Figure 62. Merck Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
Figure 63. Novo Nordisk Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
Figure 64. PolyPeptide Group Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
Figure 65. Teva Pharmaceutical Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---